ViewRay Appoints Chris A. Raanes President and CEO

              ViewRay Appoints Chris A. Raanes President and CEO

Accomplished Executive to Drive Commercial Growth of Company's MRI-Guided
Radiotherapy Technology

PR Newswire

CLEVELAND, Feb. 4, 2013

CLEVELAND, Feb. 4, 2013 /PRNewswire/ --ViewRay™ Incorporated, a privately
held medical device company, today announced that its board of directors has
appointed industry veteran Chris A. Raanes as president and CEO, effective
immediately. Raanes joins ViewRay from Accuray Incorporated, where he served
as executive vice president and chief operating officer. At ViewRay, he will
be charged with driving the worldwide commercial growth of the ViewRay system,
which provides a unique combination of simultaneous radiotherapy delivery and
continuous magnetic resonance imaging (MRI) for the treatment of cancer.

"Chris is an ideal fit for ViewRay," said company founder James F. Dempsey,
PhD, now ViewRay's chief scientific officer. "His wealth of experience in the
launch and maturation of radiation therapy devices, along with his record of
driving new clinical approaches in radiation oncology, will help to bring the
benefits of ViewRay technology to the widest possible group of patients."

With more than 14 years of experience as a senior executive in private and
public medical device companies, Raanes brings a proven track record in
commercial and operational disciplines and considerable expertise in building
global distribution channels. At Accuray, Raanes was instrumental in
transforming the company from a start-up niche player into the number three
vendor in the radiation therapy industry. He drove continuous product
innovation during his tenure, and as the company's number two executive, he
co-led Accuray's acquisition and integration of TomoTherapy Inc. in 2011.
Prior to joining Accuray, Raanes served as vice president and general manager
of imaging at PerkinElmer Optoelectronics, where he led a joint venture with
GE Healthcare, brought new technologies to market, and executed successful
partnerships with major radiation therapy vendors.

Raanes will succeed Gregory M. Ayers, MD, PhD, who successfully guided the
ViewRay system through its early commercialization and marketing clearance
from the U.S. FDA, which the company received in 2012. "On behalf of myself
and the company," said Raanes, "I want to thank Greg Ayers for all the
excellent work done so far in getting the ViewRay system ready for launch."

By using MRI technology and eliminating the radiation exposure associated with
computed tomography (CT) scans, the ViewRay system allows continuous imaging
to take place during the delivery of radiation therapy. "ViewRay is creating
an exciting new clinical paradigm," said Raanes. "No other system enables
physicians to directly view the tumor during treatment. This capability is a
significant enhancement to treatment accuracy. It also enables doctors to
track daily changes to the tumor and surrounding tissue as the treatment
progresses, and thereby to personalize their strategy for each patient. Once
clinicians discover the possibilities of the ViewRay system, we believe it
will become the new standard of care in radiation oncology." ViewRay systems
have already been acquired by the Siteman Cancer Center at Barnes‐Jewish
Hospital and Washington University School of Medicine, the UCLA Jonsson
Comprehensive Cancer Center and the University of Wisconsin Carbone Cancer

About ViewRay
ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device
company developing advanced radiation therapy technology for the treatment of
cancer. The ViewRay system provides continuous soft-tissue imaging during
treatment, using MRI-guided radiotherapy, so that clinicians are able to see
where the actual radiation dose is being delivered and adapt to changes in the
patient's anatomy. For more information, visit

ViewRay is a trademark of ViewRay Incorporated.

ViewRay acknowledges the contribution of the State of Ohio, Department of
Development and Third Frontier Commission, which provided funding in support
of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance

SOURCE ViewRay Incorporated

Contact: Michael Brandt, Senior Vice President, Sales, ViewRay Incorporated,
+1-440-703-3210, ext. 200,
Press spacebar to pause and continue. Press esc to stop.